<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37009820</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>03</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE.</ArticleTitle><Pagination><StartPage>141</StartPage><MedlinePgn>141</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">141</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-023-01350-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Haotian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Xiaozhen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, 100045, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ruijun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Wenwen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yimin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhanguo</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2590-6242</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China. li99@bjmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking-Tsinghua Center for Life Science, Beijing, China. li99@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Clinical Immunology Center, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Peking University People's Hospital, No.11 Xizhimen South Street, 100044, Beijing, China. sunxiaolin_sxl@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="Y">T-Lymphocytes, Regulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37009820</ArticleId><ArticleId IdType="pmc">PMC10068597</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01350-6</ArticleId><ArticleId IdType="pii">10.1038/s41392-023-01350-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang X, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target Ther. 2022;7:67. doi: 10.1038/s41392-022-00887-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00887-2</ArticleId><ArticleId IdType="pmc">PMC8898945</ArticleId><ArticleId IdType="pubmed">35250032</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse G, et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. Proc. Natl Acad. Sci. USA. 2017;114:7083&#x2013;7088. doi: 10.1073/pnas.1620835114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1620835114</ArticleId><ArticleId IdType="pmc">PMC5502598</ArticleId><ArticleId IdType="pubmed">28584086</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen PC, et al. Glucocorticoids decrease Treg cell numbers in lungs of allergic mice. Eur. J. Pharm. 2015;747:52&#x2013;58. doi: 10.1016/j.ejphar.2014.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2014.11.034</ArticleId><ArticleId IdType="pubmed">25499819</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandolfi J, et al. Regulatory and effector T-cells are differentially modulated by dexamethasone. Clin. Immunol. 2013;149:400&#x2013;410. doi: 10.1016/j.clim.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.09.008</ArticleId><ArticleId IdType="pubmed">24211714</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899&#x2013;911. doi: 10.1016/j.immuni.2009.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.03.019</ArticleId><ArticleId IdType="pubmed">19464196</ArticleId></ArticleIdList></Reference><Reference><Citation>Spee-Mayer CV, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2016;75:1407&#x2013;1415. doi: 10.1136/annrheumdis-2015-207776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207776</ArticleId><ArticleId IdType="pubmed">26324847</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007;178:2579&#x2013;2588. doi: 10.4049/jimmunol.178.4.2579.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.4.2579</ArticleId><ArticleId IdType="pubmed">17277168</ArticleId></ArticleIdList></Reference><Reference><Citation>Comte D, et al. Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2. Arthritis Rheumatol. 2017;69:808&#x2013;813. doi: 10.1002/art.40014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40014</ArticleId><ArticleId IdType="pmc">PMC5526072</ArticleId><ArticleId IdType="pubmed">27992687</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>